This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Nevro (NVRO) Gains Following FDA Approval for Senza HFX iQ
by Zacks Equity Research
Nevro (NVRO) gets FDA approval for its next-generation SCS system, Senza HFX iQ, for treating chronic back and leg pain.
Quest Diagnostics (DGX) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
The non-COVID base business is expected to have gained from Quest Diagnostics' (DGX) efforts to expand value-based contracts with payers.
Reasons to Retain Merit Medical (MMSI) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
Accuray's (ARAY) New Treatment Package to Boost Patient Outcome
by Zacks Equity Research
Accuray's (ARAY) latest automated breast cancer treatment package for the Radixact System is expected to extend and improve the quality of patients' lives.
What's in Store for Abbott Laboratories (ABT) in Q3 Earnings?
by Zacks Equity Research
Going by the industry-wide trend so far, logistical challenges and increasing unit costs might have weighed on the corporate profitability of Abbott (ABT) in Q3.
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the cost of products continues to rise.
Walgreens Boots (WBA) Q4 Earnings Top, Operating Loss Concerns
by Zacks Equity Research
The U.S. Healthcare segment of Walgreens Boots (WBA) grows on key contract wins, continued partnership growth and a strong focus on execution.
QuidelOrtho (QDEL) Reports Solid Preliminary Q3 Revenues
by Zacks Equity Research
QuidelOrtho's (QDEL) revenue growth in the third quarter is likely to have been boosted by continued strength in its non-COVID-19 product sales.
3 Reasons to Retain Baxter (BAX) Stock in Your Portfolio
by Zacks Equity Research
Investors remain optimistic about Baxter (BAX) due to its strong product portfolio.
3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Nevro (NVRO), owing to its strength in the global SCS market.
Thermo Fisher (TMO) Launches New TaqPath Panel in Europe
by Zacks Equity Research
This panel of Thermo Fisher (TMO), apart from detecting GI bacteria, also helps in identifying the root cause of an infection and administering the best suitable treatment fast.
Charles River's (CRL) New Launch to Boost Gene Therapy Workflow
by Zacks Equity Research
Charles River's (CRL) latest product offering is expected to streamline the pathway to GMP AAV vector manufacturing without significant process development.
4 Defensive Bets to Pacify Pessimists to Ride Market Storms
by Snehadri Nag
Here we mention four defensive stocks, namely Lamb Weston (LW), Consolidated Water, McKesson and Hershey with strong prospects to stay afloat in the bear market.
3 Reasons to Retain Allscripts (MDRX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances.
Walgreens (WBA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Walgreens (WBA) is expected to have registered growth in Q4 in its U.S. retail pharmacy business, banking on demand for vaccinations and tests amid the ongoing series of contagious virus spread.
McKesson (MCK) Stock Moves -1.2%: What You Should Know
by Zacks Equity Research
McKesson (MCK) closed at $346.68 in the latest trading session, marking a -1.2% move from the prior day.
Edwards Lifesciences (EW) TAVR Sales Strong Amid Macro Issues
by Zacks Equity Research
Edwards Lifesciences (EW) expects full-year 2022 underlying sales growth in the mid-single-digit range on the back of strength in demand for products used in more intense surgeries.
Reasons to Retain Veeva Systems (VEEV) Stock in Your Portfolio
by Zacks Equity Research
Veeva Systems' (VEEV) slew of strategic deals raises optimism about the stock.
Neogen (NEOG) Q1 Earnings Top Estimates, Operating Margin Dips
by Zacks Equity Research
Neogen's (NEOG) allergen and environmental sanitation product lines decline due to reduced buying patterns from customers and supply chain disruptions of certain products.
Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Stock Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how argenex SE (ARGX) and McKesson (MCK) have performed compared to their sector so far this year.
Here's Why You Should Retain Chemed (CHE) Stock for Now
by Zacks Equity Research
Investors are optimistic about Chemed's (CHE) Roto-Rooter business, which is witnessing continued demand for plumbing, drain cleaning services and water restoration services.
Here's Why You Should Retain Inari Medical (NARI) Stock Now
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, dependency on the wide adoption of products is a woe.
SmileDirectClub (SDC) Hurt by Lower Spending, Margin Woe
by Zacks Equity Research
The ongoing macroeconomic challenges continue to impact SmileDirectClub's (SDC) core demographic and business spending.
Intuitive Surgical (ISRG) Up After da Vinci SP's Japan Approval
by Zacks Equity Research
Intuitive Surgical (ISRG) gains approval in Japan for its single-port robotic surgical system, da Vinci SP. It will enable surgeons to provide minimally invasive experience for complex procedures.